Research programme: bladder diseases therapeutics - TARIS Biomedical
Latest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator TARIS Biomedical
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Genitourinary disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Genitourinary-disorders in USA (Intravesicular)
- 19 Dec 2019 Research programme: bladder diseases therapeutics - TARIS Biomedical is available for licensing as of 19 Dec 2019. https://tarisbiomedical.com/
- 01 Dec 2019 Early research in Genitourinary disorders in USA (Intravesicular) before December 2019 (TARIS Biomedical pipeline, December 2019)